0000000000679238

AUTHOR

Véronique Leblond

showing 3 related works from this author

Alemtuzumab Combined with Dexamethasone, Followed By Alemtuzumab Maintenance or Allo-SCT in "ultra High-risk" CLL: Final Results from the CLL2O Phase…

2014

CLL with deletion 17p (17p-) or refractory to fludarabine (F)-based regimens is characterized by poor prognosis. The cooperative French/German CLL2O study aimed at achieving deep and durable response in this population by combining alemtuzumab (A) and dexamethasone (D) induction, followed by consolidation with A maintenance or allogeneic stem-cell transplantation (allo-SCT). Induction treatment consisted of subcutaneous A (30mg, 3x weekly) combined with oral D (40 mg days 1-4 and 15-18), both at 28 day cycles, and prophylactic pegfilgrastim 6 mg on days 1 and 15. If at least SD was achieved after 3 cycles, consolidation was scheduled with either allo-SCT or A maintenance (30mg every 2 weeks…

Bendamustineeducation.field_of_studymedicine.medical_specialtybusiness.industryImmunologyPopulationPhases of clinical researchCell BiologyHematologyNeutropeniamedicine.diseaseBiochemistryGastroenterologySurgeryTransplantationMedian follow-upInternal medicinemedicineAlemtuzumabbusinesseducationPegfilgrastimmedicine.drug
researchProduct

Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study

2017

GREEN (NCT01905943) is a non-randomized, open-label phase IIIb study investigating obinutuzumab alone or plus chemotherapy in chronic lymphocytic leukemia (CLL). We report a preplanned subgroup analysis of 158 previously untreated CLL patients receiving obinutuzumab–bendamustine (G-B). Patients received six 28-day cycles (C) of G-B: obinutuzumab day (D)1/D2 of C1 (25 mg D1/975 mg D2), 1000 mg D8 and D15 of C1, and D1 of C2–6; and bendamustine 70/90 mg/m2 D1 and D2 of C1–6. The primary endpoint was safety/tolerability. Grade ≥3 adverse events (AEs) occurred in 82.3% of patients, including neutropenia (49.4%), thrombocytopenia (12.0%) and febrile neutropenia (10.8%). Serious AEs included neut…

AdultMaleBendamustineCancer Researchmedicine.medical_specialtyNeoplasm ResidualNeutropeniaAntibodies Monoclonal HumanizedGastroenterologyArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicineObinutuzumabInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineBendamustine HydrochlorideHumansSurvival rateAgedAged 80 and overSalvage Therapybusiness.industryRemission InductionHematologyMiddle AgedPrognosismedicine.diseaseLeukemia Lymphocytic Chronic B-CellMinimal residual diseaseSurvival RateTumor lysis syndromeOncologyTolerabilitychemistryDrug Resistance Neoplasm030220 oncology & carcinogenesisFemaleNeoplasm Recurrence LocalRituximabbusinessFebrile neutropeniaFollow-Up Studies030215 immunologymedicine.drugLeukemia
researchProduct

Alemtuzumab Plus Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Transplantation in Ultra High-Risk CLL: Updated Results From a…

2012

Abstract Abstract 716 CLL patients characterized by 17p-, TP53 mutation or refractoriness to fludarabine (F)-based therapy show a very poor prognosis (“ultra high-risk CLL”). Although alemtuzumab (A) showed efficacy in these cohorts, the rate and duration of remissions remain unsatisfactory. Aim of the CLL2O study was to achieve higher overall response rates (ORR) by adding high-dose dexamethasone (D) to A during induction and investigating the consolidation effect of prolonged A or allogeneic stem-cell transplantation (allo-SCT), respectively. Induction treatment consisted of subcutaneous A, 30 mg weekly × 3 for 28 days, combined with oral D, 40 mg on days 1–4 and 15–18, and prophylactic p…

Bendamustinemedicine.medical_specialtyPerformance statusbusiness.industryImmunologyPhases of clinical researchCell BiologyHematologyNeutropeniamedicine.diseaseBiochemistryGastroenterologyFludarabineSurgeryTransplantationInternal medicinemedicineAlemtuzumabbusinessPegfilgrastimmedicine.drugBlood
researchProduct